val-20240823

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 8-K

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2024

(Exact name of registrant as specified in its charter)

Delaware

001-40034

82-4369909

(State or other jurisdiction

(Commission File Number)

(IRS Employer Identification No.)

of incorporation)

2223 Avenida de la Playa, Suite 208

(Address of principal executive offices and zip code)

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	GRI	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders

On August 23, 2024, GRI Bio, Inc. (the “Company”) convened and then adjourned its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The Company previously filed a Definitive Proxy Statement, dated August 2, 2024, as amended and supplemented to date (as amended and supplemented, the “Proxy Statement”). A total of 741,914 shares of the Company’s common stock were entitled to vote on June 27, 2024, the record date for the Annual Meeting, and 256,566 shares of common stock, or approximately 34.58% of the shares entitled to vote, were present or represented by proxy at the Annual Meeting. Per the Company’s amended and restated bylaws, a quorum requires the presence, in person or by proxy, of the holders of one-third of the voting power of the stock outstanding and entitled to vote at the Annual Meeting. As a result, there was a quorum present for the Annual Meeting. The only matter submitted to a vote of stockholders at the Annual Meeting was the proposal regarding adjournment of the Annual Meeting as further described in Proxy Statement, and the voting results for this proposal are set forth below.

After the vote on this adjournment proposal, the Company adjourned the Annual Meeting to Friday, September 6, 2024 at 11:00 a.m., Eastern Time, virtually at www.virtualshareholdermeeting.com/GRI2024 to allow for the solicitation of additional proxies to adopt the remaining proposals set forth in the Proxy Statement for the Annual Meeting.

Adjournment Proposal

The proposal to approve any postponement or adjournment of the Annual Meeting, from time to time, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to adopt the proposals set forth in the proxy statement or to establish a quorum was approved as follows:


Votes For	Votes Against	Votes Abstained	Broker Non-Votes
157,455	99,095	16	—

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 23, 2024						GRI Bio, Inc.
						By: /s/ Leanne Kelly
						Leanne Kelly
						Chief Financial Officer